Medical nanotechnology in the UK: a perspective from the London Centre for Nanotechnology

Abstract 

Nanotechnology research is booming worldwide, and the general belief is that medical and biological applications will form the greatest sector of expansion over the next decade, driven by an attempt to bring radical solutions to areas of unmet medical need. What is true in the United States is also being fulfilled in Europe. This, though, is generally at a significantly lower investment level, even if for “large” capital infrastructure and interdisciplinary centers. Against this, the United Kingdom and its European partners are following the maxim “small is beautiful” and are attempting to identify and develop academic research and commercial businesses in areas that traditional nanotechnology developments involving engineering or physics find challenging. Thus in London—University College London (UCL) in a major joint project with Imperial College and linked to other UK and European centers of excellence—we are building upon our internationally competitive medical research (the two universities together form one of the largest centers of biomedical research outside the United States) to focus on and develop medical nanotechnology as a major sector of our research activity. A novel approach to commercialization has been the establishment with government and private equity funds of a “BioNanotechnology Centre” that will act as a portal for UK industry to access specialist skills to solve issues relating to developing nanotechnology-based medical applications, for example, for environmental screening, diagnostics, and therapy. This article reviews our academic and business strategy with examples from our current biomedical research portfolio.

Key words: Nanotechnology center, Nanomedicine, Bionanotechnology, Commercialization